Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.

doi:10.1158/1078-0432.ccr-03-0521

Article

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2004

Learn Chris A, Hartzell Tristan L, Wikstrand Carol J, Archer Gary E, Rich Jeremy N, Friedman Allan H, Friedman Henry S, Bigner Darell D, Sampson John H

Abstract excerpt

PURPOSE: We have reported previously that tumors expressing wild-type epidermal growth factor receptor (EGFR) in a murine model are sensitive to the EGFR tyrosine kinase inhibitor gefitinib, whereas tumors expressing mutant EGFR variant III (EGFRvIII) are resistant. Determination of how this differential inhibition occurs may be important to patient selection and treatment criteria, as well as the design of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.

Abstract excerpt

Topics

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.

Abstract excerpt

Topics

Related research